Similar articles

• [Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis].

  Aoyagi Y, Yanagi M, Asakura H. Aoyagi Y, et al. Nihon Naika Gakkai Zasshi. 1995 Dec 10;84(12):2003-7. Nihon Naika Gakkai Zasshi. 1995. PMID: 8586921 Review. Japanese. No abstract available.
• Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.

  Cui R, Wang B, Ding H, Shen H, Li Y, Chen X. Cui R, et al. Chin Med J (Engl). 2002 Jan;115(1):42-5. Chin Med J (Engl). 2002. PMID: 11930656
• [Clinical signification and evaluation of PIVKA-II in hepatocellular carcinoma].

  Matsushima A, Enomoto M, Yokoo Y, Arai M, Kobayashi T, Okuno F, Hirano Y, Sujita K, Eto S, Takagi T, et al. Matsushima A, et al. Rinsho Byori. 1989 Jun;37(6):683-6. Rinsho Byori. 1989. PMID: 2477568 Japanese. No abstract available.
• [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].

  Arima K, Kodama T, Suga M, Sakamoto H, Ohe Y, Yachi A. Arima K, et al. Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):3049-52. Gan To Kagaku Ryoho. 1989. PMID: 2476968 Japanese.
• [High risk group for development of hepatocellular carcinoma].

  Koike Y, Shiratori Y. Koike Y, et al. Nihon Rinsho. 2001 Oct;59 Suppl 6:362-6. Nihon Rinsho. 2001. PMID: 11761973 Review. Japanese. No abstract available.